Publications by authors named "Pascal Barneoud"

Claim this Profile
V
Validation of memory assessment in the Starmaze task: Data from 14 month-old APPPS1 mice and controls.
Julien Schmitt, Anne-Lise Paradis, Mathieu Boucher, Laurent Andrieu, Pascal Barnéoud

Data Brief· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flexibility as a marker of early cognitive decline in humanized apolipoprotein E ε4 (ApoE4) mice.
Julien Schmitt, Anne-Lise Paradis, Mathieu Boucher, Laurent Andrieu, Pascal Barnéoud

Neurobiol Aging· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration.
Camille Taccola, Pascal Barneoud, Sylvaine Cartot-Cotton, Delphine Valente, Nathalie Schussler

Neuropharmacology· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
An Phu Tran Nguyen, Elpida Tsika, Kaela Kelly, Nathan Levine, Xi Chen, Pascal Barneoud

Proc Natl Acad Sci U S A· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.
Bradford M Elmer, Kurt A Swanson, Dinesh S Bangari, Peter A Piepenhagen, Errin Roberts, Pascal Barneoud

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
André Malanda, Pierre-Yves Abécassis, Pascal Barnéoud, Pascale Brunel, Véronique Taupin

Data Brief· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Dominique Lesuisse, André Malanda, Jean-François Peyronel, Yannick Evanno, Patrick Lardenois

Bioorg Med Chem Lett· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, Thomas Debeir, Jean Menager, Pascal Barneoud

Alzheimers Res Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier.
Camille Taccola, Sylvaine Cartot-Cotton, Delphine Valente, Pascal Barneoud, Catherine Aubert

Eur J Pharm Sci· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.
Martine Latta-Mahieu, Bradford Elmer, Alexis Bretteville, Yaming Wang, Mati Lopez-Grancha, Pascal Barneoud

Glia· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration.
Anthony Brureau, Véronique Blanchard-Bregeon, Catherine Pech, Stéphanie Hamon, Pascal Chaillou, Pascal Barneoud

Neurobiol Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
Philippe Delay-Goyet, Véronique Blanchard, Nathalie Schussler, Mati Lopez-Grancha, Jean Ménager

Alzheimers Dement (N Y)· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C).
Gaynor A Smith, Emily M Rocha, Thomas Rooney, Pascal Barneoud, Jesse R McLean

PLoS One· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis